Bencherif SA Warren Sands R Ali OA Li WA Lewin SA Braschler TM Shih TY Verbeke CS Bhatta D Dranoff G Mooney DJ 2015 A biomaterial-based vaccination system that uses minimal extracorporeal manipulation could provide in situ enhancement of dendritic cell (DC) numbers, a physical space where DCs interface with transplanted tumour cells, and an immunogenic context. Here we encapsulate GM-CSF, serving as a DC enhancement factor, and CpG ODN, serving as a DC activating factor, into sponge-like macroporous cryogels. These cryogels are injected subcutaneously into mice to localize transplanted tumour cells and deliver immunomodulatory factors in a controlled spatio-temporal manner. These vaccines elicit local infiltrates composed of conventional and plasmacytoid DCs, with the subsequent induction of potent, durable and specific anti-tumour T-cell responses in a melanoma model. These cryogels can be delivered in a minimally invasive manner, bypass the need for genetic modification of transplanted cancer cells and provide sustained release of immunomodulators. Altogether, these findings indicate the potential for cryogels to serve as a platform for cancer cell vaccinations. application/pdf https://sonar.ch/global/documents/156111 eng info:eu-repo/semantics/altIdentifier/doi/10.1038/ncomms8556 info:eu-repo/semantics/altIdentifier/pmid/26265369 info:eu-repo/semantics/openAccess Nature communications. - 2015 Animals Cancer Vaccines Cryogels Dendritic Cells Female Melanoma Mice Mice, Inbred BALB C Mice, Inbred C57BL Neoplasms, Experimental T-Lymphocytes Injectable cryogel-based whole-cell cancer vaccines. http://purl.org/coar/resource_type/c_6501